About DiscGenics
DiscGenics is a company based in Salt Lake City (United States) founded in 2008. DiscGenics has raised $65.84 million across 3 funding rounds from investors including CareNet, Mitsubishi UFJ Capital and Medical Incubator Japan. The company has 45 employees as of December 31, 2022. DiscGenics operates in a competitive market with competitors including ViaCyte, Capricor Therapeutics, Neurona Therapeutics, EpiBone and Gamida Cell, among others.
- Headquarter Salt Lake City, United States
- Employees 45 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Discgenics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$65.84 M (USD)
in 3 rounds
-
Latest Funding Round
$50 M (USD), Series C
Aug 25, 2020
-
Investors
CareNet
& 2 more
-
Employee Count
45
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of DiscGenics
Unlock access to complete
Unlock access to complete
Leadership Team
5 people
Software Development Team
3 people
Human Resources and Administration
1 people
Unlock access to complete
Funding Insights of DiscGenics
DiscGenics has successfully raised a total of $65.84M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $50 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in DiscGenics
DiscGenics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include CareNet, Mitsubishi UFJ Capital and Medical Incubator Japan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is invested in AI, energy, and various sectors.
|
Locked | Locked | Locked | |
|
Investment in innovative healthcare startups is facilitated by this company.
|
Locked | Locked | Locked | |
|
Medical sales support and education services for pharmaceuticals are provided.
|
Locked | Locked | Locked |
Investor details for DiscGenics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DiscGenics
Investment portfolio details for DiscGenics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DiscGenics
Detailed financials for DiscGenics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Discgenics Comparisons
Peer comparison for DiscGenics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DiscGenics
DiscGenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ViaCyte, Capricor Therapeutics, Neurona Therapeutics, EpiBone and Gamida Cell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell therapy for diabetes is developed from stem cells.
|
|
| Locked | Locked | Locked |
Regenerative medicine for cardiovascular disorders is developed using cell-based platforms.
|
|
| Locked | Locked | Locked |
Cell-based therapies are developed for intractable neurological diseases.
|
|
| Locked | Locked | Locked |
Developer of stem cells to regrow damaged bones
|
|
| Locked | Locked | Locked |
Cell therapies for cancer and serious diseases are developed.
|
Detailed competitors of DiscGenics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Discgenics
Complete news archive for DiscGenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DiscGenics
DiscGenics was founded in 2008 and raised its 1st funding round 3 years after it was founded.
DiscGenics is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
DiscGenics is a funded company, having raised a total of $65.84M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at DiscGenics is 45.
DiscGenics was established in 2008 in Salt Lake City, United States, within the spinal therapeutics sector. A tissue engineering approach is employed, leveraging proprietary adult human disc stem cells to address degenerative disc disease. Two products are under development: Injectable Discogenic Cell Therapy (IDCT), an off-the-shelf allogeneic treatment for moderately degenerated discs delivered via non-surgical percutaneous injection, and Surgical Discogenic Cell Therapy (SDCT), a minimally invasive implant for herniated discs.
DiscGenics's top competitors include EpiBone, Neurona Therapeutics and Gamida Cell.
DiscGenics has 3 investors. Key investors include CareNet, Mitsubishi UFJ Capital, and Medical Incubator Japan.